



IIES MCRC
VALUE ADDITION
THROUGH EDUCATION



PharmaVISION

PharmaVISION

Educating Minds, Empowering Pharma

SEPTEMBER 2025

Pharma and Healthcare Insights

Published by

PHARMA CLUB

IES's Management College and Research Centre, Mumbai

PharmaVISION

INDIA SET TO STRENGTHEN PHARMA AND MEDICAL DEVICE COLLABORATION WITH SAUDI ARABIA

India and Saudi Arabia are set to enhance collaboration in pharmaceuticals and medical devices through Pharmexcil's strategic initiatives with the Saudi Food and Drug Authority (SFDA). The plan focuses on regulatory harmonization, faster product approvals, and transparent frameworks to boost investor confidence.

In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes.

Mounjaro's sales have soared 15 times since March, when the drug was launched in India.

Obesity and diabetes management may soon become a "blockbuster class" in India, reshaping therapy priorities for both MNCs and domestic players.



“With these collaborative initiatives gaining momentum, the India-Saudi Arabia pharmaceutical corridor is poised for robust growth...,” said a senior official, highlighting that regulatory alignment, joint ventures, and R&D will drive pharma growth under Saudi Arabia's Vision 2030.

Source: Pharmabiz.com

PHARMA EXPORTS REGISTER 7 PER CENT GROWTH IN AUGUST



India's pharmaceutical exports rose by about 7% in August 2025 to \$2.51 billion from \$2.35 billion a year earlier, as per the Ministry of Commerce and Industry. In rupee terms, exports increased 11.56% to ₹21,968 crore. Imports of medicinal and pharmaceutical products grew 1.26% to \$780.04 million, or 5.64% in rupee terms to ₹6,832.52 crore.

During April–August 2025, exports rose 7.26% to \$12.76 billion (₹1,09,784 crore) compared to \$11.89 billion (₹99,371.3 crore) last year, while imports increased 5.4% to \$3.88 billion (₹33,351.49 crore). Earlier, in April–June 2025, pharma exports registered 5.2% growth and imports 4.1%. Although August's growth was lower than July's 14%, the overall trend signals sustained momentum in India's pharmaceutical trade.

Source: Pharmabiz.com

INDIA'S GENERIC PHARMA FACES TARIFF UNCERTAINTY BUT RETAINS EDGE IN US MARKET: JPMORGAN ANALYST



India's generic pharmaceutical industry remains strong in the US market despite potential tariff uncertainties, according to JPMorgan analysts. Indian companies supply nearly half of all generics used in the US, helping reduce healthcare costs significantly. While a possible Section 232 tariff probe could impose duties, the sector is expected to withstand modest levies of up to 20% with limited impact.

However, higher tariffs beyond 25% could challenge profitability. Large players such as Sun Pharma, Cipla, and Lupin are better positioned due to their diversified global presence. Analysts also highlight the growing potential of India's contract development and manufacturing (CDMO) segment, which offers long-term structural growth opportunities and strengthens India's role as a key global supplier of affordable medicines.

Source: THE ECONOMIC TIMES

GLENMARK PHARMA SIGNS USD 18 MILLION DEAL WITH CHINESE DRUG MAKER



Glenmark Specialty signed an exclusive deal with Hengrui Pharma for Trastuzumab Rezetecan, a HER2-targeting cancer drug. The pact includes a US\$18 million upfront payment, up to US\$1.093 billion in milestones, and royalties, expanding Glenmark's oncology presence in emerging markets.

Source: ETNow



Micro Labs Chief Dilip Surana Dismantles Trump's Claim: Science Shows No Autism Risk from Paracetamol

Dilip Surana refuted Trump's paracetamol-autism claim, citing WHO's stance of no proven link, urging evidence-based use during pregnancy while reaffirming Dolo-650's leadership in India's pharma market.

Source: Pharmaleaders.tv



Lupin Manufacturing Solutions :Empagliflozin API gets CADIFA approval from ANVISA , Brazil

Lupin Manufacturing Solutions got ANVISA's CADIFA approval for its Empagliflozin API made at Vizag, strengthening its global API presence in diabetes treatment.

Source: Medical Dialogues

STRATEGIC BUSINESS UPDATES



Acquisition News: Torrent Pharma gets CCI approval to buy controlling stake in THIS chemical company

Torrent Pharmaceuticals has received approval from the Competition Commission of India (CCI) to acquire a controlling 46.39% stake in J.B. Chemicals & Pharmaceuticals Ltd for about ₹11,917 crore, along with an open offer for an additional 26% at ₹1,639 per share. The acquisition aims to enhance Torrent's presence in formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing (CDMO) services. The merger will create a stronger, more competitive entity with expanded capabilities, improved market reach, and a reinforced position in India's growing pharmaceutical sector.

Source: ETNow




Dr. Reddy's acquires STUGERON to strengthen its CNS portfolio

Dr. Reddy's has completed a definitive agreement with Johnson & Johnson to acquire the STUGERON brand and its variants—STUGERON FORTE and STUGERON PLUS—across 18 APAC and EMEA markets, including India and Vietnam. Containing Cinnarizine, used for vertigo treatment, STUGERON leads the Indian Cinnarizine market. The acquisition strengthens Dr. Reddy's Central Nervous System (CNS) portfolio and expands its presence in the anti-vertigo segment. Operations will transition smoothly, supporting the company's goal of reaching 1.5 billion patients by 2030.

Source: Express Pharma

STRATEGIC BUSINESS UPDATES

Indian Pharma in September 2025: Momentum, Disruption & Caution



The Indian pharmaceutical industry in September 2025 stood at a defining moment marked by steady growth, emerging disruptions, and a sense of caution about the future. This analysis blends insights from PharmaTrac MAT Sep 2025 data with contemporary reporting from Business Standard, Reuters, Economic Times, and other leading outlets. Despite a complex operating environment, the market continued to expand in value, driven primarily by new product launches and price-led growth rather than a rise in sales volume.

Chronic therapies such as cardiac and oncology drugs performed strongly, while acute segments slowed. Regulatory changes caused short-term disruptions in distribution and pricing. Though growth remains positive, rising scrutiny and margin pressures demand innovation and adaptability. The message of the article is clear: the Indian pharma sector retains strong momentum but must navigate disruption with prudence and foresight.

Source: Medicinman



Quiz

The future growth of pharma is strongly linked to which transformation trend?



- A** Manual Record-Keeping
- B** Digital Health & AI-driven Analytics
- C** Increased Field Visit Frequency
- D** Paper-Based Marketing Tools

Which segment currently contributes the highest share to the Indian pharma market?



- A** Branded Generics
- B** Over-the-Counter (OTC)
- C** Biosimilars
- D** APIs

Which statement best describes Pharmacoeconomics?



- A** Study of clinical trial results
- B** Study of adverse drug reactions
- C** Evaluation of drug cost vs patient outcome
- D** Study of drug synthesis

The Indian Pharma sector is popularly known as:



- A** The Innovation Hub of the World
- B** The Medicine Manufacturing Center of Asia
- C** The Pharmacy of the World
- D** The Regulatory Powerhouse





PGDM-Pharmaceutical Management

PGDM Program is a meticulously conceived industry oriented program, approved by AICTE, NBA accredited and Equivalent to MBA by AIU. It is a 2 Year Full Time Program consisting of 6 terms. PGDM-PM is a meticulously conceived industry oriented program, approved by AICTE. It offers a complete insight into the Pharmaceutical sector.

Editorial Team:

Anchal Israni

anchal.israni24@ies.edu
Phone no: 8850699342

Rohit Rane

rohit.rane24@ies.edu
Phone no: 7021304643

Sanika Narvankar

sanika.narvankar24@ies.edu
Phone no: 7249748847

Kiran Yadav

kiran.yadav24@ies.edu
Phone no: 7738192500

Ajay Kharate

ajay.kharate24@ies.edu
Phone no: 8381058570

Prapti Nagdeva

prapti.nagdeva25@ies.edu
Phone no: 93241 22779

Sunny Roy

sunny.roy25@ies.edu
Phone no: 8850790128

Janhavi Narvekar

janhavi.narvekar25@ies.edu
Phone no: 992070698

Sachi Israni

sachi.israni25@ies.edu
Phone no: 8850687300

Nishant Choudhari

nishant.choudhari25@ies.edu
Phone no: 9326191028

General Enquiry Address: IES MCRC "Vishwakarma" M.D. Lotlikar Vidya Sankul, 791, S.

K. Marg, Bandra Reclamation, Mumbai - 400 050

Registrar office / Admin Office no. - 022 - 5000 1725/ 5000 1785

For any other enquiry - ies.mcrc@ies.edu / registrar.mcrc@ies.edu